Potru R, Ahn J, Fung H, Cohen S M
Rush University Medical Center, Chicago, IL, USA.
Transplant Proc. 2009 Nov;41(9):3947-8. doi: 10.1016/j.transproceed.2009.02.087.
Although the incidence of (myelodysplastic syndrome (MDS)) is higher among heart and lung transplant recipients than the general population, the same has not been shown in liver transplant (OLT) patients. We present the second known case of MDS after OLT. Case reports of MDS in OLT were identified using PubMed. Patient data were gathered from the patient and the medical record. A 54-year-old Caucasian man underwent OLT in 2003 and again in 2004 for hepatitis C-related cirrhosis. In 2007, the patient developed weakness, malaise, and shortness of breath. Laboratory studies revealed pancytopenia. Bone marrow biopsy showed MDS, with refractory anemia and excess blasts-1. The patient underwent chemotherapy and reduction in immunosuppression without a clinical response. Our experience suggested that MDS, although rare, should be considered in the differential diagnosis of pancytopenia after OLT. Once diagnosed, immunosuppression reduction, chemotherapy, and even stem cell transplantation may be the appropriate treatment in selected candidates.
尽管与一般人群相比,心肺移植受者中骨髓增生异常综合征(MDS)的发病率更高,但肝移植(OLT)患者中尚未发现这种情况。我们报告了OLT术后第二例已知的MDS病例。使用PubMed检索了OLT术后MDS的病例报告。从患者及其病历中收集了患者数据。一名54岁的白种男性在2003年和2004年因丙型肝炎相关肝硬化接受了OLT。2007年,该患者出现乏力、不适和呼吸急促。实验室检查显示全血细胞减少。骨髓活检显示为MDS,伴有难治性贫血和原始细胞增多-1型。该患者接受了化疗并减少了免疫抑制,但无临床反应。我们的经验表明,MDS虽然罕见,但在OLT术后全血细胞减少的鉴别诊断中应予以考虑。一旦确诊,对于选定的患者,减少免疫抑制、化疗甚至干细胞移植可能是合适的治疗方法。